An enlarged prostate or BPH (benign prostatic hyperplasia) is a common affliction of older men. BPH is one of the most commonly diagnosed diseases in the male U.S. population. The condition can seriously impact the health and quality of life of older men and can lead to acute urinary retention, incontinence, and other serious consequences. It is estimated that 50% of men in their 50s have pathological signs of prostatic hyperplasia and from 26 to 46% of men between the ages of 40 to 79
Nymox has developed a new treatment for BPH, NX-1207. NX-1207 is entering Phase 3 clinical trials, the last stage before applying for FDA approval. If approved, the drug could offer new hope for the millions of men suffering from BPH.
More information about BPH for patients is available here.